10 Cancer Vaccine Companies to Watch
Cancer vaccines had a big October!
At ESMO 2026, Merck and Moderna reported that their personalized mRNA vaccine plus Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in a Phase 3 trial. That momentum reaches beyond the major players. Among the companies we’re watching, Epitopea recently dosed the first patient in its ovarian cancer vaccine trial. We used BiopharmIQ to map 60+ companies already working on cancer vaccines and identified ten developers with signals worth following! Reach out to us for the full list, with or without their contact list!
1. Transgene
Transgene raised approximately €105 million in 2025 to accelerate myvac, its individualized cancer vaccine platform. Its head and neck cancer program is in the Phase 2 portion of a randomized study.
2. Infinitopes
Infinitopes expanded its seed financing to $35 million in 2026. Its off-the-shelf vaccine, ITOP1, is being studied in oesophageal cancer, with the first patient dosed in July.
3. Elicio Therapeutics
Elicio completed a $15 million offering in July 2026. It plans to study ELI-002 7P in metastatic pancreatic cancer, building on its work in patients at risk of recurrence after treatment.
4. Valo Therapeutics
Valo secured €19 million in 2025 to expand clinical development of PeptiCRAd-1. Its approach coats an oncolytic virus with tumour antigens to stimulate an immune response.
5. Esphera SynBio
Esphera is an earlier-stage technology watch. A $2 million seed round supports its work on engineered exosomes for cancer vaccines.
6. Geneos Therapeutics
Geneos initiated IMPACT31, a randomized Phase 2 trial in patients with liver cancer at high risk of recurrence after surgery. It is testing a personalized neoantigen DNA vaccine against active surveillance.
7. Epitopea
Epitopea dosed the first patient in its Phase 1/1b trial of CryptiVax-1001 in November 2026. Its off-the-shelf RNA vaccine focuses on high-grade serous ovarian cancer.
8. Scancell
Scancell’s iSCIB1+ vaccine is moving toward a Phase 3 trial in advanced melanoma. The trial has regulatory clearance, making its start and progress important milestones to follow.
9. Immunomic Therapeutics
Immunomic dosed the first patient in a Phase 1 study of ITI-5000 in 2026. It is a self-amplifying RNA vaccine being tested in triple-negative breast cancer.
10. Metaclipse Therapeutics
Metaclipse has a newly registered Phase 1 trial for its personalized tumour-membrane vaccine in recurrent head and neck cancer. Its approach uses material from each patient’s tumour.
Explore the wider cancer vaccine landscape
These ten are a preview. We mapped 63 cancer vaccine companies in BiopharmIQ and used our MCP to help turn the data into a dashboard.
Explore the maps, cancer focus, development stages, and the ten companies featured here 👇🏻
From a question to an interactive dashboard with BiopharmIQ MCP
This watchlist began with a straightforward question submitted through BiopharmIQ MCP: Which cancer vaccine companies have a meaningful clinical, regulatory, or financing signal in 2026?
By connecting specialized BiopharmIQ data directly to an AI workflow, MCP made it possible to screen companies, compare public and private players, examine supporting signals, and turn the results into a source-linked interactive dashboard.
The value is not simply generating another list. It is being able to explore life-sciences intelligence conversationally and rapidly transform the results into a practical research asset.
Want the full company list, with or without company contacts?
Interested in trying the BiopharmIQ MCP in ChatGPT or Claude to explore company and Hot Leads data yourself? 👉🏻 Reach out to us.
Article History:
11/16/26 MD



Comments